SCHEDULE 13D/A: Panacea Venture Reduces Connect Biopharma Stake to 21.5%

Panacea Venture Healthcare Fund II, L.P. has reduced its beneficial ownership in Connect Biopharma Holdings Limited by selling 2,000,000 Ordinary Shares at $3.00 per share, now holding 21.5%.

Summary

• Panacea Venture Healthcare Fund II, L.P. and its related entities/individuals beneficially own 12,000,000 Ordinary Shares of Connect Biopharma Holdings Limited.
• This ownership represents 21.5% of the Issuer's Ordinary Shares outstanding, based on 55,903,513 shares as of October 31, 2025.
• Since Amendment No. 3, Panacea Venture Healthcare Fund II, L.P. purchased 50,000 Ordinary Shares in open market transactions at a weighted average price of $1.4641 per share.
• On November 24, 2025, Panacea Venture Healthcare Fund II, L.P. sold 2,000,000 Ordinary Shares for $3.00 per share.
• The funds used for the share purchases were obtained through capital contributions from Panacea Venture Healthcare Fund II, L.P.'s partners.

Sentiment

Score: 4

Explanation: The filing indicates a significant reduction in a major investor's stake in Connect Biopharma Holdings Limited, which can be perceived negatively by the market, even though the sale was profitable for the investor.

Positives

• The sale of 2,000,000 shares occurred at $3.00 per share, which is significantly higher than the recent purchase price of $1.4641 per share, indicating a profitable transaction for the reporting person.
• The reporting person still maintains a substantial 21.5% stake in Connect Biopharma Holdings Limited, suggesting continued, albeit reduced, interest in the company.

Negatives

• A significant reduction in beneficial ownership by a major investor (2,000,000 shares sold) could be perceived negatively by the market, potentially signaling a lack of confidence or a strategic shift.

Risks

• No specific risks related to the Issuer's operations or financial health are mentioned in this ownership filing. The primary implication is the potential market reaction to a large shareholder reducing their stake.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the Issuer's future performance or strategic direction.

Management Comments

• No direct quotes or paraphrased statements from company management of Connect Biopharma Holdings Limited are included in this filing. James Huang is identified as Founding Managing Partner of Panacea Innovation Limited and signed the filing on behalf of the reporting persons.

Industry Context

This Schedule 13D/A filing primarily concerns changes in beneficial ownership by a significant institutional investor, Panacea Venture, in Connect Biopharma Holdings Limited. It does not provide specific details on broader industry trends or competitive landscape within the biopharma sector, focusing instead on the investor's stake adjustments.

Comparison to Industry Standards

• This filing is an ownership disclosure and does not contain information that allows for a direct comparison of Connect Biopharma's operational or financial results to global industry benchmarks or specific comparable companies/projects.

Legal Proceedings

• The filing states 'None' for Item 2(d) or 2(e) regarding disclosure of legal proceedings for the reporting persons, and no legal proceedings involving the Issuer are mentioned.

Related Party Transactions

• The transactions described are open market purchases and sales of the Issuer's Ordinary Shares by Panacea Venture Healthcare Fund II, L.P. The reporting persons (Panacea Innovation Limited, Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., and James Huang) are related entities and individuals, sharing beneficial ownership of the reported shares.

Stakeholder Impact

• Shareholders: Existing shareholders may react negatively to a major investor reducing their stake, potentially leading to downward pressure on the share price.
• Company Management: May need to address market concerns if the share price is impacted by the ownership change.

Next Steps

• This filing does not explicitly mention any future actions, events, or milestones for Connect Biopharma Holdings Limited or the reporting persons beyond the disclosed transactions.

Key Dates

Recommendation

While a major investor has reduced their stake, the sale was at a significantly higher price than recent purchases, indicating a profitable exit for a portion of their holdings. The investor still retains a substantial 21.5% ownership, suggesting continued, albeit reduced, conviction. Investors should monitor the market's reaction to this ownership change and evaluate Connect Biopharma's underlying fundamentals and future prospects before making further investment decisions.

Keywords

Connect Biopharma Holdings Limited, Ordinary Shares, Schedule 13D/A, Beneficial Ownership, Panacea Venture, James Huang, Share Sale, Equity Stake, Biopharma, SEC Filing